New 6-month results from a first-in-human trial investigating the SpyGlass drug delivery platform indicated continued reductions in intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The data were highlighted in an oral presentation at the Glaucoma 360 New Horizons Forum in San Francisco on February 3.